Skip to content

Brain Network Characteristics in Patients With Disorders of Consciousness

Assessing Brain Network Characteristics in Patients With Disorders of Consciousness by Simultaneous Trimodal Positron Emission Tomography-Functional Magnetic Resonance Imaging-Electroencephalograph(PET-fMRI-EEG)Imaging

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05558670
Enrollment
40
Registered
2022-09-28
Start date
2022-09-30
Completion date
2023-10-31
Last updated
2022-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disorders of Consciousness

Keywords

PET-fMRI-EEG, brain network, coma, Vegetative state(VS), Unresponsive wakefulness syndrome (UWS), Minimally conscious state(MCS), Emerged from minimally conscious state(EMCS)

Brief summary

Simultaneous measurement of the three modalities, functional magnetic resonance imaging (fMRI), positron emission tomography (PET) and electroencephalography (EEG) was proven to be feasible and advantageous in evaluating brain structural and functional (via fMRI), metabolic (via PET) and electrophysiological (via EEG) signatures simultaneously under the same conditions. Investigators use trimodal PET-fMRI-EEG imaging to explore the characteristics of brain network damage in patients with disorders of consciousness(DOC), assess the trajectory of consciousness recovery in a prospective observational cohort study.

Interventions

OTHERPET-fMRI-EEG

Participants perform PET, fMRI, and EEG simultaneously using a MRI compatible EEG cap

Sponsors

Xijing Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Coma, VS/UWS, MCS and EMCS according to diagnostic criteria 2. Age ≥18 years 3. Written informed consent obtained

Exclusion criteria

1. Patients with contraindications to PET, MRI, EEG examinations or inability to complete PET-fMRI-EEG examinations (presence of ferromagnetic metal implants or hyperthermia) 2. Hyperglycemia that is difficult to correct 3. Patients with long-term use of corticosteroids 4. Patients with coexisting severe systemic disease and limited life expectancy

Design outcomes

Primary

MeasureTime frameDescription
CRS-R total scorePatients in coma after 3 weeks enrolledThe coma recovery scale-revised(CRS-R) total score is used to measure level of consciousness of disorder in enrolled patients. CRS-R consists of six subscales addressing auditory, visual, motor, verbal, communication, and arousal functions.The lowest item on each subscale represents reflexive activity and the highest item represents cognitively mediated behavior. Maximum scores of each subscale are summed to obtain the total score (from 0 to 23).The score for each subscale is based on the presence or absence of a specific behavioral response to a sensory stimulus (higher scores are better).
GOSE scorePatients are followed up for 6 months after enrolledGlasgow Outcome Scale-Extended(GOSE) score is used to measure the functional limitations of participants. GOSE is a 1-8 point scale (1 = Death, 2 = Vegetative State, 3 = Lower Severe Disability, 4 = Upper Severe Disability, 5 = Lower Moderate Disability, 6 = Upper Moderate Disability, 7 = Lower Good Recovery, and 8 = Upper Good Recovery). Patients with higher scores are more independent.

Countries

China

Contacts

Primary ContactRong Chen
cmuchenrong@126.com18292575563

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026